JCR Pharmaceuticals adn Alexion Announce Milestone in Neurodegenerative Disease Collaboration
TOKYO – JCR Pharmaceuticals Co., Ltd. and Alexion, a rare disease company, jointly announced today, September 19, 2024, the achievement of a milestone in their collaborative program for the growth of a novel therapy for a neurodegenerative disease. The milestone triggers a payment from Alexion to JCR Pharmaceuticals.
The collaboration, initiated in february 2022, focuses on developing a potential first-in-class therapy utilizing JCR’s proprietary antibody technology and Alexion’s expertise in rare diseases and complement biology. The specific neurodegenerative disease targeted was not disclosed.
Under the terms of the agreement, JCR is responsible for research and early development activities, while Alexion has exclusive worldwide rights to further develop and commercialize the program. The milestone achievement relates to the completion of a specified development stage, as outlined in the original agreement.
“We are pleased to announce this milestone achievement with alexion, reflecting the progress of our collaborative program,” stated a JCR Pharmaceuticals representative. “we look forward to continuing our work with Alexion to advance this potentially transformative therapy for patients with neurodegenerative diseases.”
JCR Pharmaceuticals is a research-based pharmaceutical company specializing in innovative biopharmaceuticals. Alexion, now part of AstraZeneca, focuses on developing and delivering life-changing therapies for people with rare and devastating diseases.
Investors & Media:
JCR Pharmaceuticals Co., Ltd.
Corporate Communications
ir-info@jp.jcrpharm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250919738507/en/
